Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
MAX Power Begins Historic Drilling of Canada’s First-Ever Natural Hydrogen Well
-
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
-
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
-
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Live
-
Black Friday Starts Early at Curacao: Three Weeks of Massive Savings You Can’t Miss
-
Vor Bio to Participate in Upcoming Investor Conferences
-
Vaxart to Host Upcoming Conference Calls
-
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
-
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
-
AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call
-
Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
-
Dycom Industries, Inc. to Host Fiscal 2026 Third Quarter Results Conference Call
-
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
-
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
-
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
-
ESET to aid MSPs by integrating with ConnectWise Asio
-
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
-
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA pri
-
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
-
illumin Reports Third Quarter 2025 Financial Results
-
Form 8.3 - Unite Group plc.
-
Form 8.3 - Idox
-
Form 8.3 - Empiric Student Property Plc
-
Form 8.3 - Bluefield Solar Income Fund Ltd.
-
Jackbit Sets New Benchmark for No ID Crypto Casinos
-
AIS 5G Supports The 74th Miss Universe 2025 — Welcomes Global Contestants with Special SIM Packages
-
Barrick Completes Sale of Alturas Project
-
Tree Island Renews Normal Course Issuer Bid
-
Copyseeker Pioneers Visual Search Integration in AI with Model Context Protocol Launch
-
TERRA CLEAN PROVIDES CORPORATE UPDATE
-
Almadex Announces Plans to Drill New Hope Porphyry Project, Arizona and Provides Paradise Drill Program Update
-
Holley Reports Third Quarter 2025 Results
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
-
Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
-
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
-
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
-
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
-
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
-
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
-
Nexxen to Announce Third Quarter 2025 Financial Results on November 13, 2025
-
Foremost Hat Launches 2025 Sustainable Beanie Collection for Brands and Retailers
-
Notification of managers’ transactions
-
Evergold Announces Closing of $350,000 Convertible Debenture Private Placement with CJ “Charlie” Greig; Drilling at DEM is Underway
-
Onex Reports Third Quarter 2025 Results
-
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
MADD Canada Unveils Roadside Memorial Sign in Trenton in Honour of Rebecca Beatty Killed in Impaired Driving Crash
-
Boralex announces its third quarter results and commissioning of large-scale projects in Canada
-
Lagoon Furniture at BDNY 2025 | Stylish & Durable Hospitality Design
-
Brookfield Infrastructure Reports Strong Third Quarter 2025 Results

